Retrobulbar Triamcinolone Acetonide Injection in the Treatment of NA-AION
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02329288|
Recruitment Status : Unknown
Verified March 2015 by pandongyan, Second Military Medical University.
Recruitment status was: Not yet recruiting
First Posted : December 31, 2014
Last Update Posted : March 30, 2015
NAION produces an ischemic insult in the optic nerve head presumably due to the hypoperfusion of the short ciliary arteries that supply it.
Intravenous injection of glucocorticoid have proven to be effective in treatment of Nonarteritic Anterior Ischemic Optic Neuropathy,but have some side effects. the investigators believe that offering them Retrobulbar Triamcinolone Acetonide Injection that might halt the progression of the visual acuity and visual field loss if our hypothesis is correct, would greatly improve their chances of avoiding blindness.
|Condition or disease||Intervention/treatment||Phase|
|Triamcinolone Acetonide Optic Neuropathy, Ischemic||Drug: Triamcinolone Acetonide Drug: placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Retrobulbar Triamcinolone Acetonide Injection in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy|
|Study Start Date :||May 2015|
|Estimated Primary Completion Date :||December 2015|
|Estimated Study Completion Date :||January 2016|
Active Comparator: Triamcinolone Acetonide
Drug: Triamcinolone Acetonide
Placebo Comparator: placebo
- Changes of Best corrected visual acuity(BCVA) [ Time Frame: baseline and 1month, 3month ]
- Changes of Visual Field [ Time Frame: baseline and 1month, 3month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02329288
|Contact: DONGYAN PAN, Dremail@example.com|
|Study Director:||shihong zhao||department of ophthalmology|